Characterization of somatostatin receptor expression in human pancreatic cancer using real-time RT-PCR

Journal of Surgical Research

Volumn 119, Issue 2, 2004, Pages 130-137

  Li, Min ^a   Li, Wei ^b   Kim, Hee Joon ^c   Yao, Qizhi ^a   Chen, Changyi ^a   Fisher, William E ^a  

^a BAYLOR COLLEGE OF MEDICINE   (United States)

^b SHANDONG UNIVERSITY OF TRADITIONAL CHINESE MEDICINE   (China)

^c UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

gene therapy; pancreatic adenocarcinoma; somatostatin receptors

Indexed keywords

MESSENGER RNA; SOMATOSTATIN RECEPTOR; SOMATOSTATIN RECEPTOR 1; SOMATOSTATIN RECEPTOR 2; SOMATOSTATIN RECEPTOR 3; SOMATOSTATIN RECEPTOR 4; SOMATOSTATIN RECEPTOR 5;

ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; DOWN REGULATION; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; PANCREAS; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA EXTRACTION;

ADENOCARCINOMA; CELL LINE, TUMOR; DOWN-REGULATION; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; PANCREATIC NEOPLASMS; RECEPTORS, SOMATOSTATIN; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER;

EID: 2442446577     PISSN: 00224804     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jss.2004.03.006     Document Type: Article

References (35)

1. Landis S.H., Murray T., Bolden S., et al. Cancer statistics, 1998. CA Cancer J Clin. 48:(1):1998;6
2. Vernejoul F., Faure P., Benali N., et al. Antitumor effect of in vivo somatostatin receptor subtype 2 gene transfer in primary and metastatic pancreatic cancer models. Cancer Res. 62:(21):2002;6124
3. Torrisani J., Buscail L. Molecular pathways of pancreatic carcinogenesis. Ann. Pathol. 22:(5):2002;349
4. Warshaw A.L., Fernandez-del Castillo C. Pancreatic carcinoma. N. Engl. J. Med. 326:(7):1992;455
5. Fisher W.E., Berger D.H. Angiogenesis and antiangiogenic strategies in pancreatic cancer. Int. J. Gastrointest. Cancer. 33:(1):2003;79
6. Bousquet C., Puente E., Buscail L., et al. Antiproliferative effect of somatostatin and analogs. Chemotherapy. 47:(Suppl. 2):2001;30
7. Hejna M., Schmidinger M., Raderer M. The clinical role of somatostatin analogues as antineoplastic agents Much ado about nothing. Ann. Oncol. 13:(5):2002;653
8. Benali N., Ferjoux G., Puente E., et al. Somatostatin receptors. Digestion. 62:(Suppl. 1):2001;27
9. Fisher W.E., Doran T.A., Muscarella P. 2nd, et al. Expression of somatostatin receptor subtype 1-5 genes in human pancreatic cancer. J. Natl. Cancer Inst. 90:(4):1998;322
10. Yamada Y., Stoffel M., Espinosa R. 3rd, et al. Human somatostatin receptor genes localization to human chromosomes 14, 17, and 22 and identification of simple tandem repeat polymorphisms. Genomics. 15:(2):1993;449
11. Cordelier P., Esteve J.P., Bousquet C., et al. Characterization of the antiproliferative signal mediated by the somatostatin receptor subtype sst5. Proc. Natl. Acad. Sci. USA. 94:(17):1997;9343
12. Buscail L., Esteve J.P., Saint-Laurent N., et al. Inhibition of cell proliferation by the somatostatin analogue RC-160 is mediated by somatostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc. Natl. Acad. Sci. USA. 92:(5):1995;1580
13. Zatelli M.C., Piccin D., Tagliati F., et al. Somatostatin receptor subtype 1 selective activation in human growth hormone (GH)- and prolactin (PRL)-secreting pituitary adenomas Effects on cell viability, GH, and PRL secretion. J. Clin. Endocrinol. Metab. 88:(6):2003;2797
14. Kikutsuji T., Harada M., Tashiro S., et al. Expression of somatostatin receptor subtypes and growth inhibition in human exocrine pancreatic cancers. J. Hepatobiliary Pancreat. Surg. 7:(5):2000;496
15. Guillermet J., Saint-Laurent N., Rochaix P., et al. Somatostatin receptor subtype 2 sensitizes human pancreatic cancer cells to death ligand-induced apoptosis. Proc. Natl. Acad. Sci. USA. 100:(1):2003;155
16. Rochaix P., Delesque N., Esteve J.P., et al. Gene therapy for pancreatic carcinoma local and distant antitumor effects after somatostatin receptor sst2 gene transfer. Hum. Gene Ther. 10:(6):1999;995
17. Rauly I., Saint-Laurent N., Delesque N., et al. Induction of a negative autocrine loop by expression of sst2 somatostatin receptor in NIH 3T3 cells. J. Clin. Invest. 97:(8):1996;1874
18. Fisher W.E., Wu Y., Amaya F., et al. Somatostatin receptor subtype 2 gene therapy inhibits pancreatic cancer in vitro. J. Surg. Res. 105:(1):2002;58
19. Celinski S.A., Fisher W.E., Amaya F., et al. Somatostatin receptor gene transfer inhibits established pancreatic cancer xenografts. J. Surg. Res. 115:(1):2003;41
20. Zambre Y., Ling Z., Chen M.C., et al. Inhibition of human pancreatic islet insulin release by receptor-selective somatostatin analogs directed to somatostatin receptor subtype 5. Biochem. Pharmacol. 57:(10):1999;1159
21. Szepeshazi K., Schally A.V., Halmos G., et al. Targeting of cytotoxic somatostatin analog AN-238 to somatostatin receptor subtypes 5 and/or 3 in experimental pancreatic cancers. Clin. Cancer Res. 7:(9):2001;2854
22. Sharma K., Patel Y.C., Srikant C.B. Subtype-selective induction of wild-type p53 and apoptosis, but not cell cycle arrest, by human somatostatin receptor 3. Mol. Endocrinol. 10:(12):1996;1688
23. Dizeyi N., Konrad L., Bjartell A., et al. Localization and mRNA expression of somatostatin receptor subtypes in human prostatic tissue and prostate cancer cell lines. Urol. Oncol. 7:(3):2002;91
24. Hansson J., Bjartell A., Gadaleanu V., et al. Expression of somatostatin receptor subtypes 2 and 4 in human benign prostatic hyperplasia and prostatic cancer. Prostate. 53:(1):2002;50
25. Canobbio L., Boccardo F., Cannata D., et al. Treatment of advanced pancreatic carcinoma with the somatostatin analogue BIM 23014. Preliminary results of a pilot study. Cancer. 69:(3):1992;648
26. van Eijck C.H., Lamberts S.W., Lemaire L.C., et al. The use of somatostatin receptor scintigraphy in the differential diagnosis of pancreatic duct cancers and islet cell tumors. Ann. Surg. 224:(2):1996;119
27. Reubi J.C., Lamberts S.W., Maurer R. Somatostatin receptors in normal and tumoral tissue. Horm. Res. 29:(2-3):1998;65
28. Fekete M., Redding T.W., Comaru-Schally A.M., et al. Receptors for luteinizing hormone-releasing hormone, somatostatin, prolactin, and epidermal growth factor in rat and human prostate cancers and in benign prostate hyperplasia. Prostate. 14:(3):1989;191
29. Fekete M., Bajusz S., Groot K., et al. Comparison of different agonists and antagonists of luteinizing hormone-releasing hormone for receptor-binding ability to rat pituitary and human breast cancer membranes. Endocrinology. 124:(2):1989;946
30. Buscail L., Saint-Laurent N., Chastre E., et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res. 56:(8):1996;1823
31. Rocheville M., Lange D.C., Kumar U., et al. Subtypes of the somatostatin receptor assemble as functional homo- and heterodimers. J. Biol. Chem. 275:(11):2000;7862
32. Redding T.W., Schally A.V. Inhibition of growth of pancreatic carcinomas in animal models by analogs of hypothalamic hormones. Proc. Natl. Acad. Sci. USA. 81:(1):1984;248
33. Zalatnai A., Schally A.V. Responsiveness of the hamster pancreatic cancer to treatment with microcapsules of D-Trp-6-LH-RH and somatostatin analog RC-160. Histological evidence of improvement. Int. J. Pancreatol. 4:(2):1989;149
34. Tirone T.A., Fagan S.P., Templeton N.S., et al. Insulinoma-induced hypoglycemic death in mice is prevented with beta cell-specific gene therapy. Ann. Surg. 233:(5):2001;603
35. Ray M.K., Fagan S.P., Moldovan S., et al. Development of a transgenic mouse model using rat insulin promoter to drive the expression of CRE recombinase in a tissue-specific manner. Int. J. Pancreatol. 25:(3):1999;157